Kite Pharma, Inc. has amended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to include emerging research in immune response to tumor neo-antigens, tumor-specific antigens associated with genetic mutations. Also, new T cell receptor (TCR) and new chimeric antigen receptor (CAR) product candidates targeting solid tumors have been added to the collaboration. The amendment provides additional product candidates for Kite’s pipeline.   The ad...